Format

Send to

Choose Destination
Expert Opin Ther Pat. 2017 Jun;27(6):657-666. doi: 10.1080/13543776.2017.1259412. Epub 2016 Nov 21.

Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).

Author information

1
a Centro de Investigaciones Biologicas-CSIC , Translational Medicinal and Biological Chemistry Laboratory , Madrid , Spain.

Abstract

Glycogen synthase kinase (GSK-3) is a serine/threonine kinase that phosphorylates more than one hundred different sequences within proteins in a variety of different pathways. It is a key component of a remarkably large number of cellular processes and diseases. Imbalance of GSK-3 activity is involved in various prevalent pathological diseases, such as diabetes, neurodegenerative diseases and cancer. Understanding its role in different disorders has been central in the last several decades and there has been a significantly large development of GSK-3 inhibitors, some of which, show promising results for the treatment of these devastating diseases. Areas covered: This review covers patent literature on GSK-3 inhibitors and their applications published and/or granted between 2014 and 2015. Expert opinion: GSK-3 inhibitors have gained a prominent role in regenerative medicine based in their ability to modulate stem cells. Moreover, some allosteric modulators of GSK-3 emerge as safe compounds for chronic treatments.

KEYWORDS:

Alzheimer’s disease; GSK-3 inhibitors; cancer; regenerative medicine; stem cells

PMID:
27828716
DOI:
10.1080/13543776.2017.1259412
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center